Ibio Inc (IBIO) 1.77 $IBIO
IBio (IBIO) Is Today's Dead Cat Bounce Stock
at The Street - Wed Oct 22, 8:49AM CDT
Trade-Ideas LLC identified iBio (IBIO) as a "dead cat bounce" (down big yesterday but up big today) candidate
IBIO: 1.77 (+0.03)
iBio Expands Exclusive Product Collaboration With Novici Biotech
Marketwired - Wed Oct 22, 7:32AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, and Novici Biotech LLC (Novici) have agreed to broaden their commercial collaboration, currently focused on antibodies and certain vaccine products, to include iBio's proprietary IBIO-CFB03 product for idiopathic pulmonary fibrosis, systemic sclerosis and other fibrotic diseases. This expanded program will combine the strength of the iBioLaunch(TM) platform with Novici's patented GRAMMR(R) technology for rapid evolution of gene sequences to significantly increase expression yield of target proteins.
IBIO: 1.77 (+0.03)
Ebola Stocks May Be Overpriced as Fundamentals Outweigh Fear
at The Street - Tue Oct 21, 5:10AM CDT
Ebola stocks have soared in recent weeks but a closer look at fundamentals may serve as a reality check for investors playing the story.
RAI: 61.35 (+0.32), IBIO: 1.77 (+0.03)
Why iBio (IBIO) Stock Is Plummeting Today
at The Street - Mon Oct 20, 9:45AM CDT
Shares of pharmaceutical company iBio (IBIO) plunged in morning trading Monday after some positive announcements about the Ebola outbreak.
IBIO: 1.77 (+0.03)
How to Trade the Market's Most-Active Stocks
at The Street - Fri Oct 17, 2:18PM CDT
Here's how to trade some of the most active stocks on the market today.
GE: 25.19 (-0.26), HAL: 54.43 (-1.23), IBIO: 1.77 (+0.03)
Why iBio (IBIO) Stock Continues to Soar Today
at The Street - Fri Oct 17, 9:33AM CDT
Shares of iBio (IBIO) surged again in morning trading Friday as the Ebola outbreak continues.
IBIO: 1.77 (+0.03)
Why iBio (IBIO) Stock Is Soaring Today
at The Street - Thu Oct 16, 8:58AM CDT
Shares of iBio (IBIO) soared in morning trading Thursday after the company announced it has offered to aid the U.S. government in fighting Ebola with its proprietary antibody production technology.
IBIO: 1.77 (+0.03)
iBio Responds to Inquiries About its Role in Emergency Response to Ebola Virus Disease Outbreak
Marketwired - Thu Oct 16, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO) today confirmed, in response to shareholder and media inquiries: (i) the applicability of its issued U.S. iBioLaunch(TM) platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus, and (ii) that iBio has an ongoing relationship with Caliber Biotherapeutics LLC reflected by a License and Collaboration Agreement dated February 14, 2013 pursuant to which iBio and Caliber have been collaborating on commercial opportunities for recombinant antibodies and antibody-related proteins based on the speed, efficiency, and cost advantages of producing pharmaceutical proteins in plants instead of with bioreactor-based manufacturing methods.
IBIO: 1.77 (+0.03)
Market Maker Surveillance Report. AHPI, APT, LAKE, IBIO, CDXS, MPO, Losing Stocks With Lowest Price Friction For Tuesday, October 14th 2014
M2 - Wed Oct 15, 3:11AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4904 companies with "abnormal" market making, 2632 companies with positive Friction Factors and 2319 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Allied Healthcare Products Inc (NASDAQ:AHPI), Alpha Pro Tech Ltd (NYSE:APT), Lakeland Industries Inc (NASDAQ:LAKE), Ibio Inc (NYSE:IBIO), Codexis Inc (NASDAQ:CDXS), Midstates Petroleum Company Inc (NYSE:MPO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
APT: 4.30 (-0.40), AHPI: 2.08 (-0.03), MPO: 3.11 (-0.06), CDXS: 2.36 (+0.06), IBIO: 1.77 (+0.03), LAKE: 13.13 (-1.81)
Why Versar (VSR) Stock Is Soaring Today
at The Street - Tue Oct 14, 11:03AM CDT
Versar (VSR) stock is sharply up today as other Ebola-related stocks tumble following a mixed report by the World Health Organization.
APT: 4.30 (-0.40), VSR: 3.27 (-0.24), LAKE: 13.13 (-1.81), IBIO: 1.77 (+0.03)
Market Maker Surveillance Report. S, BTU, IBIO, VALE, SIMH, FB, Bullishly Biased Price Friction For Monday, October 13th 2014
M2 - Tue Oct 14, 4:08AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4783 companies with "abnormal" market making, 1672 companies with positive Friction Factors and 3138 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. Sprint Nextel Corp (NYSE:S), Peabody Energy Corp (NYSE:BTU), Ibio Inc (NYSE:IBIO), Vale SA (NYSE:VALE), SANOMEDICS INTERNATIONAL HOL (OTC:SIMH), Facebook Inc (NASDAQ:FB). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
BTU: 10.31 (-0.54), FB: 78.37 (-0.32), VALE: 10.82 (+0.07), S: 6.06 (-0.18), IBIO: 1.77 (+0.03)
Why iBio (IBIO) Stock Hit a One-Year High Today
at The Street - Mon Oct 13, 9:39AM CDT
Shares of iBio (IBIO) were soaring in morning trading Monday after a nurse in Texas was diagnosed with the Ebola virus, which deepened concerns about an outbreak in the U.S.
IBIO: 1.77 (+0.03)
iBio Reports on Filing of 2014 Annual Report
Marketwire - Fri Oct 03, 4:00PM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced, as required by Section 610(b) of the NYSE MKT Company Guide, that the Company's Annual Report on Form 10-K was filed with the Securities and Exchange Commission on September 29, 2014, and that its audited consolidated financial statements for the fiscal year ended June 30, 2014 contained therein included a going concern qualification from its independent public accounting firm. This announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the fiscal year ended June 30, 2014. The Company recommends examination of the Company's complete Annual Report for a better understanding of the Company and its audited consolidated financial statements.
IBIO: 1.77 (+0.03)
ACHN, IBIO, CRAY, IBCA, QLTY, PIY Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Sep 16, 6:08AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Achillion Pharmaceuticals Inc (NASDAQ:ACHN), Ibio Inc (NYSE:IBIO), Cray Inc (NASDAQ:CRAY), Intervest Bancshares Corp (NASDAQ:IBCA), Quality Distribution Inc (NASDAQ:QLTY), Preferredplus Trust Series Czn 1 (NYSE
IY) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
PIY: 25.94 (+0.38), QLTY: 11.60 (-0.70), ACHN: 11.06 (-0.37), IBIO: 1.77 (+0.03), IBCA: 9.70 (+0.02), CRAY: 28.46 (-0.39)
iBio names Dr Thomas A. Medsger Jr to clinical advisory board
M2 - Wed Sep 03, 5:56AM CDT
Biotechnology company iBio (NYSE MKT:IBIO) revealed on Tuesday the addition of Dr Thomas A. Medsger Jr, MD to its clinical advisory board.
IBIO: 1.77 (+0.03)
Dr. Thomas A. Medsger Jr. Joins iBio Clinical Advisory Board
Marketwire - Tue Sep 02, 7:32AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of biotechnology for developing and manufacturing plant-made pharmaceutical products, has appointed Thomas A. Medsger Jr., M.D., to its clinical advisory board.
IBIO: 1.77 (+0.03)
Yellow Fever - Therapeutics Pipeline Review, H2 2014 - 6 Companies & 5 Drug Profiles
M2 - Mon Sep 01, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x2n27t/yellow_fever) has announced the addition of the "Yellow Fever - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Yellow Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Yellow Fever and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Yellow Fever - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Yellow Fever and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Yellow Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Yellow Fever pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Panacea Biotec Limited - Janssen Pharmaceuticals, Inc. - NewLink Genetics Corporation - iBio, Inc. - Arbovax, Inc. - Themis Bioscience GmbH Drug Profiles - Flaviviruses Infection Vaccine - LCTA-949 - DiTU - BG-323 - yellow fever [YF-17D] (polyvalent) vaccine For more information visit http://www.researchandmarkets.com/research/x2...llow_fever
NLNK: 39.82 (+5.32), IBIO: 1.77 (+0.03)
iBio Receives European Patent Allowances for Protein Expression Technology
Marketwire - Thu Aug 28, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, received notices of intention to grant for two European patent applications claiming novel protein expression technologies.
IBIO: 1.77 (+0.03)
iBio Enters Into $10 Million Common Stock Purchase Agreement With Aspire Capital
Marketwire - Tue Aug 26, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, today announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC. Within two business days of approval of the transaction by the NYSE MKT, Aspire Capital will complete an initial purchase of 1,136,354 shares of common stock at $0.44 per share, the closing sale price of iBio's common stock on the NYSE MKT on the business day prior to entry into the purchase agreement with Aspire Capital, for proceeds of $500,000. After the SEC declares a registration statement effective relating to the transaction, Aspire Capital has committed to purchase up to $9.5 million in additional shares of common stock over a 24 month period. No warrants are associated with this agreement.
IBIO: 1.77 (+0.03)
IBio (IBIO) Is Today's Dead Cat Bounce Stock
at The Street - Wed Oct 22, 8:49AM CDT
Trade-Ideas LLC identified iBio (IBIO) as a "dead cat bounce" (down big yesterday but up big today) candidate
IBIO: 1.77 (+0.03)
iBio Expands Exclusive Product Collaboration With Novici Biotech
Marketwired - Wed Oct 22, 7:32AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, and Novici Biotech LLC (Novici) have agreed to broaden their commercial collaboration, currently focused on antibodies and certain vaccine products, to include iBio's proprietary IBIO-CFB03 product for idiopathic pulmonary fibrosis, systemic sclerosis and other fibrotic diseases. This expanded program will combine the strength of the iBioLaunch(TM) platform with Novici's patented GRAMMR(R) technology for rapid evolution of gene sequences to significantly increase expression yield of target proteins.
IBIO: 1.77 (+0.03)
Ebola Stocks May Be Overpriced as Fundamentals Outweigh Fear
at The Street - Tue Oct 21, 5:10AM CDT
Ebola stocks have soared in recent weeks but a closer look at fundamentals may serve as a reality check for investors playing the story.
RAI: 61.35 (+0.32), IBIO: 1.77 (+0.03)
Why iBio (IBIO) Stock Is Plummeting Today
at The Street - Mon Oct 20, 9:45AM CDT
Shares of pharmaceutical company iBio (IBIO) plunged in morning trading Monday after some positive announcements about the Ebola outbreak.
IBIO: 1.77 (+0.03)
How to Trade the Market's Most-Active Stocks
at The Street - Fri Oct 17, 2:18PM CDT
Here's how to trade some of the most active stocks on the market today.
GE: 25.19 (-0.26), HAL: 54.43 (-1.23), IBIO: 1.77 (+0.03)
Why iBio (IBIO) Stock Continues to Soar Today
at The Street - Fri Oct 17, 9:33AM CDT
Shares of iBio (IBIO) surged again in morning trading Friday as the Ebola outbreak continues.
IBIO: 1.77 (+0.03)
Why iBio (IBIO) Stock Is Soaring Today
at The Street - Thu Oct 16, 8:58AM CDT
Shares of iBio (IBIO) soared in morning trading Thursday after the company announced it has offered to aid the U.S. government in fighting Ebola with its proprietary antibody production technology.
IBIO: 1.77 (+0.03)
iBio Responds to Inquiries About its Role in Emergency Response to Ebola Virus Disease Outbreak
Marketwired - Thu Oct 16, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO) today confirmed, in response to shareholder and media inquiries: (i) the applicability of its issued U.S. iBioLaunch(TM) platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus, and (ii) that iBio has an ongoing relationship with Caliber Biotherapeutics LLC reflected by a License and Collaboration Agreement dated February 14, 2013 pursuant to which iBio and Caliber have been collaborating on commercial opportunities for recombinant antibodies and antibody-related proteins based on the speed, efficiency, and cost advantages of producing pharmaceutical proteins in plants instead of with bioreactor-based manufacturing methods.
IBIO: 1.77 (+0.03)
Market Maker Surveillance Report. AHPI, APT, LAKE, IBIO, CDXS, MPO, Losing Stocks With Lowest Price Friction For Tuesday, October 14th 2014
M2 - Wed Oct 15, 3:11AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4904 companies with "abnormal" market making, 2632 companies with positive Friction Factors and 2319 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Allied Healthcare Products Inc (NASDAQ:AHPI), Alpha Pro Tech Ltd (NYSE:APT), Lakeland Industries Inc (NASDAQ:LAKE), Ibio Inc (NYSE:IBIO), Codexis Inc (NASDAQ:CDXS), Midstates Petroleum Company Inc (NYSE:MPO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
APT: 4.30 (-0.40), AHPI: 2.08 (-0.03), MPO: 3.11 (-0.06), CDXS: 2.36 (+0.06), IBIO: 1.77 (+0.03), LAKE: 13.13 (-1.81)
Why Versar (VSR) Stock Is Soaring Today
at The Street - Tue Oct 14, 11:03AM CDT
Versar (VSR) stock is sharply up today as other Ebola-related stocks tumble following a mixed report by the World Health Organization.
APT: 4.30 (-0.40), VSR: 3.27 (-0.24), LAKE: 13.13 (-1.81), IBIO: 1.77 (+0.03)
Market Maker Surveillance Report. S, BTU, IBIO, VALE, SIMH, FB, Bullishly Biased Price Friction For Monday, October 13th 2014
M2 - Tue Oct 14, 4:08AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4783 companies with "abnormal" market making, 1672 companies with positive Friction Factors and 3138 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. Sprint Nextel Corp (NYSE:S), Peabody Energy Corp (NYSE:BTU), Ibio Inc (NYSE:IBIO), Vale SA (NYSE:VALE), SANOMEDICS INTERNATIONAL HOL (OTC:SIMH), Facebook Inc (NASDAQ:FB). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
BTU: 10.31 (-0.54), FB: 78.37 (-0.32), VALE: 10.82 (+0.07), S: 6.06 (-0.18), IBIO: 1.77 (+0.03)
Why iBio (IBIO) Stock Hit a One-Year High Today
at The Street - Mon Oct 13, 9:39AM CDT
Shares of iBio (IBIO) were soaring in morning trading Monday after a nurse in Texas was diagnosed with the Ebola virus, which deepened concerns about an outbreak in the U.S.
IBIO: 1.77 (+0.03)
iBio Reports on Filing of 2014 Annual Report
Marketwire - Fri Oct 03, 4:00PM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced, as required by Section 610(b) of the NYSE MKT Company Guide, that the Company's Annual Report on Form 10-K was filed with the Securities and Exchange Commission on September 29, 2014, and that its audited consolidated financial statements for the fiscal year ended June 30, 2014 contained therein included a going concern qualification from its independent public accounting firm. This announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the fiscal year ended June 30, 2014. The Company recommends examination of the Company's complete Annual Report for a better understanding of the Company and its audited consolidated financial statements.
IBIO: 1.77 (+0.03)
ACHN, IBIO, CRAY, IBCA, QLTY, PIY Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Sep 16, 6:08AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Achillion Pharmaceuticals Inc (NASDAQ:ACHN), Ibio Inc (NYSE:IBIO), Cray Inc (NASDAQ:CRAY), Intervest Bancshares Corp (NASDAQ:IBCA), Quality Distribution Inc (NASDAQ:QLTY), Preferredplus Trust Series Czn 1 (NYSE
IY) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: PIY: 25.94 (+0.38), QLTY: 11.60 (-0.70), ACHN: 11.06 (-0.37), IBIO: 1.77 (+0.03), IBCA: 9.70 (+0.02), CRAY: 28.46 (-0.39)
iBio names Dr Thomas A. Medsger Jr to clinical advisory board
M2 - Wed Sep 03, 5:56AM CDT
Biotechnology company iBio (NYSE MKT:IBIO) revealed on Tuesday the addition of Dr Thomas A. Medsger Jr, MD to its clinical advisory board.
IBIO: 1.77 (+0.03)
Dr. Thomas A. Medsger Jr. Joins iBio Clinical Advisory Board
Marketwire - Tue Sep 02, 7:32AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of biotechnology for developing and manufacturing plant-made pharmaceutical products, has appointed Thomas A. Medsger Jr., M.D., to its clinical advisory board.
IBIO: 1.77 (+0.03)
Yellow Fever - Therapeutics Pipeline Review, H2 2014 - 6 Companies & 5 Drug Profiles
M2 - Mon Sep 01, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x2n27t/yellow_fever) has announced the addition of the "Yellow Fever - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Yellow Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Yellow Fever and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Yellow Fever - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Yellow Fever and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Yellow Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Yellow Fever pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Panacea Biotec Limited - Janssen Pharmaceuticals, Inc. - NewLink Genetics Corporation - iBio, Inc. - Arbovax, Inc. - Themis Bioscience GmbH Drug Profiles - Flaviviruses Infection Vaccine - LCTA-949 - DiTU - BG-323 - yellow fever [YF-17D] (polyvalent) vaccine For more information visit http://www.researchandmarkets.com/research/x2...llow_fever
NLNK: 39.82 (+5.32), IBIO: 1.77 (+0.03)
iBio Receives European Patent Allowances for Protein Expression Technology
Marketwire - Thu Aug 28, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, received notices of intention to grant for two European patent applications claiming novel protein expression technologies.
IBIO: 1.77 (+0.03)
iBio Enters Into $10 Million Common Stock Purchase Agreement With Aspire Capital
Marketwire - Tue Aug 26, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, today announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC. Within two business days of approval of the transaction by the NYSE MKT, Aspire Capital will complete an initial purchase of 1,136,354 shares of common stock at $0.44 per share, the closing sale price of iBio's common stock on the NYSE MKT on the business day prior to entry into the purchase agreement with Aspire Capital, for proceeds of $500,000. After the SEC declares a registration statement effective relating to the transaction, Aspire Capital has committed to purchase up to $9.5 million in additional shares of common stock over a 24 month period. No warrants are associated with this agreement.
IBIO: 1.77 (+0.03)
